Preclinical imaging of mammary intraepithelial neoplasia with positron emission tomography

Journal of Mammary Gland Biology and Neoplasia

Volumn 11, Issue 2, 2006, Pages 137-149

  Abbey, Craig K ^a,b   Borowsky, Alexander D ^c,d   Gregg, Jeffery P ^c,d   Cardiff, Robert D ^c,d   Cherry, Simon R ^a  

^a University of California   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Mammary intraepithelial neoplasia; Positron emission tomography; Preclinical imaging; Therapeutic response

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 3' FLUORO 3' DEOXYTHYMIDINE F 18; COPPER 64; FLUORODEOXYGLUCOSE F 18; RAPAMYCIN; TRACER; UNCLASSIFIED DRUG;

CARCINOMA IN SITU; CORRELATION ANALYSIS; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; EXPERIMENTAL DESIGN; IMAGE PROCESSING; IMAGE RECONSTRUCTION; INTRADUCTAL CARCINOMA; METASTASIS; NONHUMAN; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; RADIOLOGICAL PARAMETERS; REVIEW; SAMPLE SIZE; STATISTICAL ANALYSIS; TRANSGENIC ANIMAL;

ANIMALS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FLUORODEOXYGLUCOSE F18; LONGITUDINAL STUDIES; LYMPHATIC METASTASIS; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; POSITRON-EMISSION TOMOGRAPHY; WHOLE-BODY COUNTING;

EID: 33846331592     PISSN: 10833021     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10911-006-9020-6     Document Type: Review

References (60)

1. Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM. Ductal carcinoma in situ of the breast. N Engl J Med 2004;350(14):1430-41.
2. Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004;6(1):17-32.
3. Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P, et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA 2003;100(10):5974-9.
4. Kavanaugh CJ, Desai KV, Calvo A, Brown PH, Couldrey C, Lubet R, et al. Pre-clinical applications of transgenic mouse mammary cancer models. Transgenic Research 2002;11:617-33.
5. Cardiff RD, Moghanaki D, Jensen RA. Genetically engineered mouse models of mammary intraepithelial neoplasia. J Mammary Gland Biol Neoplasia 2000;5(4):421-37.
6. Brown RS, Leung JY, Fisher SJ, Frey KA, Ethier SP, Wahl RL. Intratumoral distribution of tritiated-FDG in breast carcinoma: Correlation between Glut-1 expression and FDG uptake. J Nucl Med 1996;37:1042-7.
7. Ingvar M, Eriksson L, Rogers GA, Stone-Elander S, Widén L. Rapid feasibility studies of tracers for positron emission tomography: high-resolution PET in small animals with kinetic analysis. J Cereb Blood Flow Metab 1991;11:926-31.
8. Marriott CJ, Cadorette JE, Lecomte R, Scasnar V, Rousseau J, van Lier JE. High-resolution PET imaging and quantitation of pharmaceutical biodistributions in a small animal using avalanche photodiode detectors. J Nucl Med 1994;35:1390-6.
9. Cherry SR, Shao Y, Silverman RW, Meadors K, Siegel S, Chatziioannou A, et al. MicroPET: A high resolution PET scanner for imaging small animals. IEEE Trans Nucl Sci 1997;44:1161-6.
10. Jones T. The imaging science of positron emission tomography. Eur J Nucl Med 1996;23:807-13.
11. Phelps ME. Positron emission tomography provides molecular imaging of biological processes. Proc Natl Acad Sci USA 2000; 97:9226-33.
12. Tai YC, Laforest R. Instrumentation aspects of animal PET. Annu Rev Biomed Eng 2005;7:255-85.
13. Phelps ME, Mazziotta J, Schelbert HR, editors. Positron emission tomography and autoradiography: Principles and applications for the brain and heart. New York: Raven; 1986.
14. Wahl RL, editor. Principles and practice of positron emission tomography. Baltimore, Maryland: Williams & Wilkins; 2002.
15. Bailey DL, Townsend DW, Valk PE, Maisey MN, editors. Positron emission tomography: Basic sciences. Berlin Heidelberg New York: Springer; 2005.
16. Chatziioannou AF. Instrumentation for molecular imaging in preclinical research: Micro-PET and micro-SPECT. Proc Am Thorac Soc 2005;2(6):533-6.
17. Yang DJ, Kim EE, Inoue T. Targeted molecular imaging in oncology. Ann Nucl Med 2006;20(1):1-11.
18. Seddon BM, Workman P. The role of functional and molecular imaging in cancer drug discovery and development. Br J Radiol 2003;76 (Spec no 2):S128-38.
19. Czernin J, Weber WA, Herschman HR. Molecular imaging in the development of cancer therapeutics. Annu Rev Med 2006;57:99-118.
20. Dilworth SM. Polyoma virus middle T antigen and its role in identifying cancer-related molecules. Nat Rev Cancer 2002;2(12):951-6.
21. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: A transgenic mouse model for metastatic disease. Mol Cell Biol 1992;12:954-61.
22. Qiu TH, Chandramouli GV, Hunter KW, Alkharouf NW, Green JE, Liu ET. Global expression profiling identifies signatures of tumor virulence in MMTV-PyMT-transgenic mice: Correlation to human disease. Cancer Res 2004;64(17):5973-81.
23. Maglione JE, McGoldrick ET, Young LJ, Namba R, Gregg JP, Liu L, et al. Polyomavirus middle T-induced mammary intraepithelial neoplasia outgrowths: Single origin, divergent evolution, and multiple outcomes. Mol Cancer Ther 2004;3(8):941-53.
24. Kinahan PE, Rogers JG. Analytic three-dimensional image reconstruction using all detected events. IEEE Trans Nucl Sci 1990;36:964-8.
25. Lewitt RM, Muehllehner G, Karp JS. Three-dimensional reconstruction for PET by multi-slice rebinning and axial image filtering. Phys Med Biol 1994;39:321-40.
26. Xu XL, Liow JS, Strother SC. Iterative algebraic reconstruction algorithms for emission computed tomography: A unified framework and its application to positron emission tomography. Med Phys 1993;20(6):1675-84.
27. Qi J, Leahy RM, Cherry SR, Chatziioannou A, Farquhar TH. High resolution 3D Bayesian image reconstruction using the microPET small-animal scanner. Phys Med Biol 1998;43:1001-13.
28. Chatziioannou A, Qi J, Moore A, Annala A, Nguyen K, Leahy RM, et al. Comparison of 3-D maximum a posteriori and filtered backprojection algorithms for high-resolution animal imaging with microPET. IEEE Trans Med Imag 2000;19(5):507-12.
29. Di Chiro G, Brooks RA. PET quantitation: Blessing and curse. J Nucl Med 1988;29(9):1603-4.
30. Keyes JW, Jr. SUV: Standard uptake or silly useless value? J Nucl Med 1995;36(10):1836-9.
31. Coleman RE. Is quantitation necessary for oncological PET studies. Eur J Nucl Med Mol Imaging 2002;29(1):133-5.
32. Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: Variations with body weight and a method for correction. Radiology 1993;189(3):847-50.
33. Toyama H, Ichise M, Liow J-S, Vines DC, Seneca NM, Modell KJ, et al. Evaluation of anesthesia effects on [18 F]FDG uptake in mouse brain and heart using small animal PET. Nucl Med Biol 2004;31:251-6.
34. Abbey CK, Borowsky AD, McGoldrick ET, Gregg JP, Maglione JE, Cardiff RD, et al. In vivo positron-emission tomography imaging of progression and transformation in a mouse model of mammary neoplasia. Proc Natl Acad Sci USA 2004;101 (31):11438-43.
35. Abbey CK, Borowsky AD, McGoldrick ET, Gregg JP, Cardiff RD, Cherry, SR. PET Imaging of development and malignant transformation in a mouse model of mammary intraepithelial neoplasia. In: Amini AA, Manduca A, editors. Medical imaging 2005: Physiology, function, and structure from medical images, Proc SPIE 2005, vol. 5746, p. 1-9.
36. Diggle PJ, Heagerty P, Liang K-Y, Zeger SL. Analysis of longitudinal data. 2nd ed. Oxford: Oxford University Press; 2002.
37. Efron B, Tibshirani RJ. An introduction to the bootstrap. New York: Chapman & Hall; 1993.
38. Bjornsti MA, Houghton PJ. The TOR pathway: A target for cancer therapy. Nat Rev Cancer 2004;4:335-48.
39. Hidalgo M, Rowinsky EK. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 2000;19:6680-6.
40. Namba R, Young LJT, Abbey CK, Kim L, Damonte P, Borowsky AD, et al. Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of DCIS. Clin Cancer Res 2006;12(8):2613-21.
41. Namba R, Young LJ, Maglione JE, McGoldrick ET, Liu S, Wurz GT, et al. Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ. Breast Cancer Res 2005;7(6):R881-9.
42. Van Dyke T, Jacks T. Cancer modeling in the modern era: Progress and challenges. Cell 2002;108:135-44.
43. Borowsky AD, Namba R, Young LJ, Hunter KW, Hodgson JG, Tepper CG, et al. Syngeneic mouse mammary carcinoma cell lines: Two closely related cell lines with divergent metastatic behavior. Clin Exp Metastasis 2005;22(1):47-59.
44. Cheung ATW, Young LJT, Chen PCY, Chao CY, Ndoye A, Barry PA, et al. Microcirculation and metastasis in a mouse mammary tumor model system. Int J Oncol 1997;129:507-16.
45. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998;4(11):1334-6.
46. Barthel H, Cleij MC, Collingridge DR, Hutchinson OC, Osman S, He Q, et al. 3′-deoxy-3′-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 2003;63(13):3791-8.
47. Waldherr C, Mellinghoff IK, Tran C, Halpern BS, Rozengurt N, Safaei A, et al. Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3′-deoxy-3′-18F-fluorothymidine PET. J Nucl Med 2005;46(1):114-20.
48. Kubota K, Tada M, Yamada S, Hori K, Saito S, Iwata R, et al. Comparison of the distribution of fluorine-18 fluoromisonidazole, deoxyglucose and methionine in tumour tissue. Eur J Nucl Med 1999;26(7):750-7.
49. Bentzen L, Keiding S, Horsman MR, Gronroos T, Hansen SB, Overgaard J. Assessment of hypoxia in experimental mice tumours by [18F]fluoromisonidazole PET and pO2 electrode measurements. Influence of tumour volume and carbogen breathing. Acta Oncol 2002;41(3):304-12.
50. Wyss MT, Honer M, Schubiger PA, Ametamey SM. NanoPET imaging of [(18)F]fluoromisonidazole uptake in experimental mouse tumours. Eur J Nucl Med Mol Imaging 2006;33(3):311-8.
51. Lewis MR, Wang M, Axworthy DB, Theodore LJ, Mallet RW, Fritzberg AR, et al. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy. J Nucl Med 2003;44(8):1284-92.
52. Smith SV. Molecular imaging with copper-64. J Inorg Biochem 2004;98(11):1874-901.
53. Townsend DW, Cherry SR. Combining anatomy and function: The path to true image fusion. Eur Radiol 2001;11:1968-74.
54. Goertzen AL, Meadors AK, Silverman RW, Cherry SR. Simultaneous molecular and anatomical imaging of the mouse in vivo. Phys Med Biol 2002;47(24):4315-28.
55. Del Guerra A, Belcari N. Advances in animal PET scanners. Q J Nucl Med 2002;46(1):35-47.
56. Shao Y, Cherry SR, Farahani K, Meadors K, Siegel S, Silverman RW, et al. Simultaneous PET and MR imaging. Phys Med Biol 1997;42(10):1965-70.
57. Garlick PB, Marsden PK, Cave AC, Parkes HG, Slates R, Shao Y, et al. PET and NMR dual acquisition (PANDA): Applications to isolated, perfused rat hearts. NMR Biomed 1997;10(3):138-42.
58. Pichler BJ, Judenhofer MS, Catana C, Walton JH, Kneilling M, Nutt RE, et al. Performance test of a LSO-APD Detector in a 7 Tesla MRI Scanner for simultaneous PET-MR imaging. J Nucl Med 2006;47(4):639-47.
59. Schoder H, Erdi YE, Larson SM, Yeund HWD. PET/CT: A new imaging technology in nuclear medicine. Eur J Nucl Med Mol Imaging 2003;30:1419-37.
60. Ell PJ. The contribution of PET/CT to improved patient management. Br J Radiol 2006;79(937):32-6.